Three medical oncologists at Florida Cancer Specialists & Research Institute co-author a new integrated safety analysis of umbralisib, used to treat lymphoid malignancies.
Fort Myers, FL – October 14, 2021–Florida Cancer Specialists & Research Institute (FCS) director of Clinical Research, Gustavo Fonseca, MD, FACP, director of Drug Development, Manish Patel, MD, and James Reeves, MD, a member of the FCS clinical research team, participated in a new integrated safety analysis of umbralisib, used to treat lymphoid malignancies.
The study, “Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies,” was recently published online in Blood Advances.
Low rates of immune-mediated toxicities were observed with umbralisib and no cumulative toxicities were reported. The analysis concluded, “The favorable long-term tolerability profile and low rates of immune-mediated toxicities support the potential use of umbralisib for the benefit of a broad population of patients with lymphoid malignancies.”